MORRISVLLE, N.C. — nContact Surgical, a startup led by two medical device company veterans and a former chief executive officer of Pharmanetics, has closed on $7.5 million in Series B funding.

Backers of nContact include Intersouth Partners, Massey Burch Capital, Finistere Partners, Village Ventures and Tall Oaks Capital.

nContact is focused on development of a minimally invasive procedure to treat patients requiring tissue coagulation in order to improve and prolong quality of life, according to the firm’s website. The company is working with surgeons and interventional physicians on the technology.

“We’re private so we keep everything quiet,” said John Funkhouser, president and CEO of nContact. “You will need to get that information from the venture capitalists,” he said, referring to the funding. Funkhouser declined to comment further when contacted by WRAL Local Tech Wire.

Funkhouser’s most recent position was as president and CEO of Pharmanetics. He has more than 20 years of experience in the life science industry. Pharmanetics developed tests for use in the proper dosing of anticoagulant drugs.

The firm’s two co-founders also co-founded Converge Medical in 1998. Converge focused on development of couplers to be used in coronary artery bypass grafting surgery.

James Whayne, vice president of research and clinicals at nContact, has worked at Boston Scientific and the University of Virginia Health Sciences Center. He has received more than 120 patents for medical devices used in treatment of cardiac diseases. He graduated from Duke University in 1990 with a degree in biomedical and electrical engineering.

Sidney Fleischman, vice president for development and operations at nContact, also worked at Boston Scientific. He has more than 80 patents for medical devices. He is a graduate of the University of California at Santa Barbara with a degree in mechanical engineering.

Private Equity Wire first reported the deal on Monday, citing a regulatory funding.

nContact: www.ncontact.com